UNASSIGNED:本研究的目的是通过超声结合Wnt家族成员10A(WNT10A)基因预测甲状腺乳头状微小癌(PTMC)的侵袭能力,为评估PTMC的侵袭能力提供参考依据。
未经证实:从182例单发PTMC患者中收集癌组织,根据病灶是否侵犯甲状腺囊或有无淋巴结转移分为有创组和无创组。检测WNT10A蛋白的表达。年龄,性别,最大结节直径,彩色多普勒血流显像(CDFI),结节回声,微钙化,纵横比,形态(边界),结节位置,内部结构,超声怀疑淋巴结转移(US-LNM),比较侵袭组和非侵袭组之间的WNT10A表达。进行单因素分析和多因素logistic回归分析,p值小于0.05表明差异有统计学意义。
UNASSIGNED:(1)无创性组中36例患者高表达,66例患者低表达或无表达,而侵袭组中54例患者表现出高表达,26例患者表现出低表达或无表达,表明WNT10A在侵袭组中的表达水平高于非侵袭组,两组比较差异有统计学意义(P<0.01)。(2)单因素分析显示,侵袭性PTMC组和非侵袭性PTMC组年龄差异有统计学意义。性别,最大结节直径,微钙化,US-LNM和高WNT10A表达。(3)多因素分析显示,影响PTMC患者侵袭性的危险因素包括年龄<45岁,最大结节直径>7毫米,微钙化,US-LNM和高WNT10A表达。
未经证实:PTMC侵袭的危险因素包括年龄<45岁,最大结节直径>7毫米,微钙化,US-LNM和高WNT10A表达。超声检查与WNT10A基因分析相结合可为评估PTMC的侵袭能力提供参考依据。
The purpose of this study was to predict the invasiveness of papillary thyroid microcarcinoma (PTMC) via ultrasonography in combination with the Wnt family member 10A (
WNT10A) gene to provide a reference basis for evaluating the invasive capability of PTMC.
Cancer tissue were collected from 182 patients with unifocal PTMC, and the patients were divided into the invasive group and the non-invasive group based on whether the lesions invaded the thyroid capsules or whether lymph node metastasis occurred. The expression of
WNT10A protein was examined. Age, sex, maximum nodule diameter, color Doppler flow imaging (CDFI), nodule echo, microcalcification, aspect ratio, morphology (boundary), nodule location, internal structure, ultrasound-suspected lymph node metastasis (US-LNM), and WNT10A expression were compared between the invasive group and the non-invasive group. Univariate analysis and multivariate logistic regression analysis were performed, and a p value of less than 0.05 indicated that the difference was statistically significant.
(1) 36 patients in the non-invasive group showed high expression and 66 patients showed low or no expression, while 54 patients in the invasive group showed high expression and 26 patients showed low or no expression, suggesting that the expression level of
WNT10A was higher in the invasive group than in the non-invasive group, with a statistically significant difference between the two groups (P<0.01). (2) Univariate analysis showed that there were statistically significant differences between the invasive PTMC group and the non-invasive group in age, sex, maximum nodule diameter, microcalcification, US-LNM and high
WNT10A expression. (3) Multivariate analysis showed that the risk factors for invasiveness in patients with PTMC included age < 45 years, maximum nodule diameter > 7 mm, microcalcification, US-LNM and high WNT10A expression.
The risk factors for PTMC invasiveness included age < 45 years, maximum nodule diameter >7 mm, microcalcification, US-LNM and high WNT10A expression. A combination of ultrasonography and
WNT10A gene analysis could provide a reference basis for evaluating the invasive capability of PTMC.